A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

March 12, 2017

Study Completion Date

March 12, 2017

Conditions
Virus Diseases
Interventions
PROCEDURE

Blood draw

Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.

Trial Locations (1)

546700

GSK Investigational Site, Mengshan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02991872 - A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children | Biotech Hunter | Biotech Hunter